Drugs that contain Esketamine Hydrochloride

1. List of Spravato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592207 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2027

(4 years from now)

US8785500 JANSSEN PHARMS Intranasal administration of ketamine to treat depression
Mar, 2033

(10 years from now)

US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(11 years from now)

US10869844 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

US11311500 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

US11173134 JANSSEN PHARMS Methods for the treatment of depression
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 5, 2024
New Indication (I) Jul 31, 2023

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; Treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks

Dosage: SPRAY;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic